Advances in methods for assessing tumor hypoxia in vivo: Implications for treatment planning

Cancer and Metastasis Reviews

Volumn 25, Issue 3, 2006, Pages 469-480

  Davda, Sonal ^a   Bezabeh, Tedros ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Electron paramagnetic resonance; Infrared spectroscopy; Magnetic resonance imaging; Magnetic resonance spectroscopy; Positron emission tomography; Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 NITROIMIDAZOLE; ARABINOSIDE; BRU 59 21; CARBOHYDRATE DERIVATIVE; COPPER 64; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE)COPPER; ETANIDAZOLE PENTAFLUORIDE; FLUORINE 18; FLUORINE DERIVATIVE; FLUORO 2 DEOXY 1BETA DEXTRO ARABINOFURANOSYL 5 ETHYL URACIL F 18; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROETANIDAZOLE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINE 123; IODINE 124; IODOAZOMYCIN ARABINOSIDE; IODOAZOMYCIN ARABINOSIDE I 123; NEW DRUG; NITROIMIDAZOLE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; OXYGEN 15; PX 478; RADIOISOTOPE; TECHNETIUM 99M; TETROFOSMIN TC 99M; THIOSEMICARBAZONE DERIVATIVE; UNINDEXED DRUG; WATER;

ANGIOGENESIS; ELECTRON SPIN RESONANCE; HALF LIFE TIME; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMAGING SYSTEM; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MICROELECTRODE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN TENSION; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TUMOR; TUMOR CELL; TUMOR HYPOXIA;

CELL HYPOXIA; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS;

EID: 33845534152     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-006-9009-z     Document Type: Review

References (106)

1. Thomlinson, R. H., & Gray, L. H. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer, 9, 539-549.
2. Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. (1953). The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. British Journal of Radiology, 26, 638-648.
3. Kimura, H., Braun, R. D., Ong, E. T., Hsu, R., Secomb, T. W., Papahadjopoulos, D. et al. (1996). Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Research, 56, 5522-5528.
4. 2 gradients in window chamber tumours: Impact on tumour hypoxia. British Journal of Cancer, 79, 1717-1722.
5. 2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology, 26, 45-50.
6. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Dodge, R. K., Charles, H. C. et al. (1996). Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Research, 56, 5347-5350.
7. Nordsmark, M., Overgaard, M., & Overgaard, J. (1996). Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 41, 31-39.
8. Bhattacharya, A., Toth, K., Mazurchuk, R., Spernyak, J. A., Slocum, H. K., Pendyala, L. et al. (2004). Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clinical Cancer Research, 10, 8005-8017.
9. Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003). Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treatment Reviews, 29, 297-307.
10. Cowen, R. L., Williams, K. J., Chinje, E. C., Jaffar, M., Sheppard, F. C., Telfer, B. A. et al. (2004). Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: Reversing tumor radioresistance and effecting cure. Cancer Research, 64, 1396-1402.
11. Rofstad, E. K., Sundfor, K., Lyng, H., & Trope, C. G. (2000). Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. British Journal of Cancer, 83, 354-359.
12. Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H. et al. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 14, 831-838.
13. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R. et al. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research, 56, 941-943.
14. Brurberg, K. G., Graff, B. A., & Rofstad, E. K. (2003). Temporal heterogeneity in oxygen tension in human melanoma xenografts. British Journal of Cancer, 89, 350-356.
15. Urano, M., Chen, Y., Humm, J., Koutcher, J. A., Zanzonico, P., & Ling, C. (2002). Measurements of tumor tissue oxygen tension using a time-resolved luminescence-based optical oxylite probe: Comparison with a paired survival assay. Radiation Research, 158, 167-173.
16. Koch, C. J., & Evans, S. M. (2003). Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Advances in Experimental Medicine and Biology, 510, 285-292.
17. Rasey, J. S., Grunbaum, Z., Magee, S., Nelson, N. J., Olive, P. L., Durand, R. E. et al. (1987). Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiation Research, 111, 292-304.
18. Bentzen, L., Keiding, S., Horsman, M. R., Falborg, L., Hansen, S. B., & Overgaard, J. (2000). Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography - a study evaluating [18F]Fluoro-2-deoxy-d-glucose. Acta Oncologica, 39, 629-637.
19. Sorensen, M., Horsman, M. R., Cumming, P., Munk, O. L., & Keiding, S. (2005). Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. International Journal of Radiation Oncology, Biology, Physics, 62, 854-861.
20. Bruehlmeier, M., Roelcke, U., Schubiger, P. A., & Ametamey, S. M. (2004). Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. Journal of Nuclear Medicine, 45, 1851-1859.
21. Graham, M. M., Peterson, L. M., Link, J. M., Evans, M. L., Rasey, J. S., Koh, W. J. et al. (1997). Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. Journal of Nuclear Medicine, 38, 1631-1636.
22. Yang, D. J., Wallace, S., Cherif, A., Li, C., Gretzer, M. B., Kim, E. E. et al. (1995). Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology, 194, 795-800.
23. Lehtio, K., Oikonen, V., Gronroos, T., Eskola, O., Kalliokoski, K., Bergman, J. et al. (2001). Imaging of blood flow and hypoxia in head and neck cancer: Initial evaluation with [(15)O]H(2)O and [(18)F] fluoroerythronitroimidazole PET. Journal of Nuclear Medicine, 42, 1643-1652.
24. Barthel, H., Wilson, H., Collingridge, D. R., Brown, G., Osman, S., Luthra, S. K. et al. (2004). In vivo evaluation of [18F] fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. British Journal of Cancer, 90, 2232-2242.
25. Ziemer, L. S., Evans, S. M., Kachur, A. V., Shuman, A. L., Cardi, C. A., Jenkins, W. T. et al. (2003). Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. European Journal of Nuclear Medicine and Molecular Imaging, 30, 259-266.
26. Evans, S. M., Kachur, A. V., Shiue, C. Y., Hustinx, R., Jenkins, W. T., Shive, G. G. et al. (2000). Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F] EF1. Journal of Nuclear Medicine, 41, 327-336.
27. Piert, M., Machulla, H. J., Picchio, M., Reischl, G., Ziegler, S., Kumar, P. et al. (2005). Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside. Journal of Nuclear Medicine, 46, 106-113.
28. Sorger, D., Patt, M., Kumar, P., Wiebe, L. I., Barthel, H., Seese A. et al. (2003). [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nuclear Medicine and Biology, 30, 317-326.
29. Eschmann, S. M., Paulsen, F., Reimold, M., Dittmann, H., Welz, S., Reischl, G. et al. (2005). Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. Journal of Nuclear Medicine, 46, 253-260.
30. Fujibayashi, Y., Taniuchi, H., Yonekura, Y., Ohtani, H., Konishi, J., & Yokoyama, A. (1997). Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. Journal of Nuclear Medicine, 38, 1155-1160.
31. Obata, A., Yoshimi, E., Waki, A., Lewis, J. S., Oyama, N., Welch, M. J. et al. (2001). Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Annals of Nuclear Medicine, 15, 499-504.
32. O'Donoghue, J. A., Zanzonico, P., Pugachev, A., Wen, B., Smith-Jones, P., Cai, S. et al. (2005). Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. International Journal of Radiation Oncology, Biology, Physics, 61, 1493-1502.
33. Chao, K. S., Bosch, W. R., Mutic, S., Lewis, J. S., Dehdashti, F., Mintun, M. A. et al. (2001). A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 49, 1171-1182.
34. Dehdashti, F., Mintun, M. A., Lewis, J. S., Bradley, J., Govindan, R., Laforest, R. et al. (2003). In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. European Journal of Nuclear Medicine and Molecular Imaging, 30, 844-850.
35. Dehdashti, F., Grigsby, P. W., Mintun, M. A., Lewis, J. S., Siegel, B. A., & Welch, M. J. (2003). Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response - a preliminary report. International Journal of Radiation Oncology, Biology, Physics, 55, 1233-1238.
36. Lewis, J., Laforest, R., Buettner, T., Song, S., Fujibayashi, Y., Connett, J. et al. (2001). Copper-64-diacetyl-bis (N4-methylthiosemicarbazone): An agent for radiotherapy. Proceedings of the National Academy of Sciences of the United States of America, 98, 1206-1211.
37. Obata, A., Kasamatsu, S., Lewis, J. S., Furukawa, T., Takamatsu, S., Toyohara, J. et al. (2005). Basic characterization of (64) Cu-ATSM as a radiotherapy agent. Nuclear Medicine and Biology, 32, 21-28.
38. Mazure, N. M., Brahimi-Horn, M. C., Berta, M. A., Benizri, E., Bilton, R. L., Dayan, F. et al. (2004). HIF-1: Master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochemical Pharmacology, 68, 971-980.
39. Theodoropoulos, V. E., Lazaris, A. Ch., Sofras, F., Gerzelis, I., Tsoukala, V., Ghikonti, I. et al. (2004). Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. European Urology, 46, 200-208.
40. Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S., Nadrowitz, R., Richter, E. et al. (2003). The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene, 22, 3213-3220.
41. Birner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rossler, K., Prodinger, A. et al. (2001). Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer, 92, 165-171.
42. Sohda, M., Ishikawa, H., Masuda, N., Kato, H., Miyazaki, T., Nakajima, M. et al. (2004). Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. International Journal of Cancer, 110, 838-844.
43. Pili, R., & Donehower, R. C. (2003). Is HIF-1 alpha a valid therapeutic target? Journal of the National Cancer Institute, 95, 498-499.
44. Wen, B., Burgman, P., Zanzonico, P., O'donoghue, J., Cai, S., Finn, R. et al. (2004). A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. European Journal of Nuclear Medicine and Molecular Imaging, 31, 1530-1538.
45. Serganova, I., Doubrovin, M., Vider, J., Ponomarev, V., Soghomonyan, S., Beresten, T. et al. (2004). Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Research, 64, 6101-6108.
46. Rajendran, J. G., & Krohn, K. A. (2005). Imaging hypoxia and angiogenesis in tumors. Radiologic Clinics of North America, 43, 169-187.
47. Collingridge, D. R., Carroll, V. A., Glaser, M., Aboagye, E. O., Osman, S., Hutchinson, O. C. et al. (2002). The development of [(124)I] iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Research, 62, 5912-5919.
48. Czernin, J., & Phelps, M. E. (2002). Positron emission tomography scanning: Current and future applications. Annual Review of Medicine, 53, 89-112.
49. Parliament, M. B., Chapman, J. D., Urtasun, R. C., McEwan, A. J., Golberg, L., Mercer, J. R. et al. (1992). Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: Preliminary report of a clinical study. British Journal of Cancer, 65, 90-95.
50. Urtasun, R. C., Parliament, M. B., McEwan, A. J., Mercer, J. R., Mannan, R. H., Wiebe, L. I. et al. (1996). Measurement of hypoxia in human tumours by non-invasive SPECT imaging of iodoazomycin arabinoside. British Journal of Cancer. Supplement, 27, S209-S212.
51. Iyer, R. V., Kim, E., Schneider, R. F., Chapman, J. D. (1998). A dual hypoxic marker technique for measuring oxygenation change within individual tumors. British Journal of Cancer, 78, 163-169.
52. Ballinger, J. R., Kee, J. W., & Rauth, A. M. (1996). In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. Journal of Nuclear Medicine, 37, 1023-1031.
53. Melo, T., Duncan, J., Ballinger, J. R., & Rauth, A. M. (2000). BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. Journal of Nuclear Medicine, 41, 169-176.
54. Hoebers, F. J., Janssen, H. L., Olmos, A. V., Sprong, D., Nunn, A. D., Balm, A. J. et al. (2002). Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21. European Journal of Nuclear Medicine and Molecular Imaging, 29, 1206-1211.
55. Chu, T., Li, R., Hu, S., Liu, X., & Wang, X. (2004). Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)- propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker. Nuclear Medicine and Biology, 31, 199-203.
56. Cook, G. J., Houston, S., Barrington, S. F., & Fogelman, I. (1998). Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG. Journal of Nuclear Medicine, 39, 99-103.
57. Honess, D. J., Hill, S. A., Collingridge, D. R., Edwards, B., Brauers, G., Powell, N. A. et al. (1998). Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo. International Journal of Radiation Oncology, Biology, Physics, 42, 731-735.
58. Liu, Z., Stevenson, G. D., Barrett, H. H., Kastis, G. A., Bettan, M., Furenlid L. R. et al. (2004). Imaging recognition of multidrug resistance in human breast tumors using 99mTc-labeled monocationic agents and a high-resolution stationary SPECT system. Nuclear Medicine and Biology, 31, 53-65.
59. Bouziotis, P., Fani, M., Archimandritis, S. C., Loundos, G., Paravatou, M., Bicknell, R. et al. (2003). Samarium-153 and technetium-99m-labeled monoclonal antibodies in angiogenesis for tumor visualization and inhibition. Anticancer Research, 23, 2167-2171.
60. Yang, D. J., Kim, K. D., Schechter, N. R., Yu, D. F., Wu, P., Azhdarinia, A. et al. (2002). Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biotherapy & Radiopharmaceuticals, 17, 233-245.
61. Kurhanewicz, J., Vigneron, D. B., Hricak, H., Narayan, P., Carroll, P., & Nelson, S. J. (1996). Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology, 198, 795-805.
62. Star-Lack, J. M., Adalsteinsson, E., Adam, M. F., Terris, D. J., Pinto, H. A., Brown, J. M. et al. (2000). In vivo 1H MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements. American Journal of Neuroradiology, 21, 183-193.
63. Bhujwalla, Z. M., & Glickson, J. D. (1996). Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. International Journal of Radiation Oncology, Biology, Physics, 36, 635-639.
64. Jordan, B. F., Black, K., Robey, I. F., Runquist, M., Powis, G., & Gillies, R. J. (2005). Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR in Biomedicine, 18, 430-439.
65. Duong, T. Q., Iadecola, C., & Kim, S. G. (2001). Effect of hyperoxia, hypercapnia, and hypoxia on cerebral interstitial oxygen tension and cerebral blood flow. Magnetic Resonance in Medicine, 45, 61-70.
66. Zhao, D., Ran, S., Constantinescu, A., Hahn, E. W., & Mason, R. P. (2003). Tumor oxygen dynamics: Correlation of in vivo MRI with histological findings. Neoplasia, 5, 308-318.
67. Van der Sanden, B. P., Heerschap, A., Simonetti, A. W., Rijken, P. F., Peters, H. P., Stuben, G. et al. (1999). Characterization and validation of noninvasive oxygen tension measurements in human glioma xenografts by 19F-MR relaxometry. International Journal of Radiation Oncology, Biology, Physics, 44, 649-658.
68. McNab, J. A., Yung, A. C., & Kozlowski, P. (2004). Tissue oxygen tension measurements in the Shionogi model of prostate cancer using (19) F MRS and MRI. MAGMA, 17, 288-295.
69. Mason, R. P., Rodbumrung, W., & Antich, P. P. (1996). Hexafluorobenzene: A sensitive 19F NMR indicator of tumor oxygenation. NMR in Biomedicine, 9, 125-134.
70. Dardzinski, B. J., & Sotak, C. H. (1994). Rapid tissue oxygen tension mapping using 19F inversion-recovery echo-planar imaging of perfluoro-15-crown-5-ether. Magnetic Resonance in Medicine, 32, 88-97.
71. McIntyre, D. J. O, McCoy, C. L., & Griffiths, J. R. (1999). Tumor oxygen measurements by 19F magnetic resonance imaging of perfluorocarbons. Current Science, 76, 753-762.
72. Hunjan, S., Zhao, D., Constantinescu, A., Hahn, E. W., Antich, P. P., & Mason, R. P. (2001). Tumor oximetry: Demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. International Journal of Radiation Oncology, Biology, Physics, 49, 1097-1108.
73. Milosevic, M. F., Fyles, A. W., Wong, R., Pintilie, M., Kavanagh, M. C., Levin, W. et al. (1998). Interstitial fluid pressure in cervical carcinoma: Within tumor heterogeneity and relation to oxygen tension. Cancer, 82, 2418-2426.
74. Noth, U., Rodrigues, L. M., Robinson, S. P., Jork, A., Zimmermann, U., Newell, B. et al. (2004). In vivo determination of tumor oxygenation during growth and in response to carbogen breathing using 15C5-loaded alginate capsules as fluorine-19 magnetic resonance imaging oxygen sensors. International Journal of Radiation Oncology, Biology, Physics, 60, 909-919.
75. Noth, U., Grohn, P., Jork, A., Zimmermann, U., Haase, A., & Lutz, J. (1999). 19F-MRI in vivo determination of the partial oxygen pressure in perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and different tissues. Magnetic Resonance in Medicine, 42, 1039-1047.
76. Zimmermann, U., Thurmer, F., Jork, A., Weber, M., Mimietz, S., Hillgartner, M. et al. (2001). A novel class of amitogenic alginate microcapsules for long-term immunoisolated transplantation. Annals of the New York Academy of Sciences, 944, 199-215.
77. Kwock, L., Gill, M., McMurry, H. L., Beckman, W., Raleigh, J. A., & Joseph, A. P. (1992). Evaluation of a fluorinated 2-nitroimidazole binding to hypoxic cells in tumor-bearing rats by 19F magnetic resonance spectroscopy and immunohistochemistry. Radiation Research, 129, 71-78.
78. Salmon, H. W., & Siemann, D. W. (2004). Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiotherapy and Oncology, 73, 359-366.
79. Aboagye, E. O., Maxwell, R. J., Horsman, M. R., Lewis, A. D., Workman, P., Tracy, M. et al. (1998). The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. British Journal of Cancer, 77, 65-70.
80. Seddon, B. M., Maxwell, R. J., Honess, D. J., Grimshaw, R., Raynaud, F., Tozer, G. M. et al. (2002). Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clinical Cancer Research, 8, 2323-2335.
81. Seddon, B. M., Payne, G. S., Simmons, L., Ruddle, R., Grimshaw, R., Tan, S. et al. (2003). A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clinical Cancer Research, 9, 5101-5112.
82. Vaupel, P., Schaefer, C., & Okunieff, P. (1994). Intracellular acidosis in murine fibrosarcomas coincides with ATP depletion, hypoxia, and high levels of lactate and total Pi. NMR in Biomedicine, 7, 128-136.
83. Saitoh, J., Sakurai, H., Suzuki, Y., Muramatsu, H., Ishikawa, H., Kitamoto, Y. et al. (2002). Correlations between in vivo tumor weight, oxygen pressure, 31P NMR spectroscopy, hypoxic microenvironment marking by beta-D-iodinated azomycin galactopyranoside (beta-D-IAZGP), and radiation sensitivity. International Journal of Radiation Oncology, Biology, Physics, 54, 903-909.
84. Robinson, S. P., Howe, F. A., Stubbs, M., Griffiths, J. R. (2000). Effects of nicotinamide and carbogen on tumour oxygenation, blood flow, energetics and blood glucose levels. British Journal of Cancer, 82, 2007-2014.
85. Ogawa, S., Lee, T. M., Nayak, A. S., & Glynn, P. (1990). Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magnetic Resonance in Medicine, 14, 68-78.
86. 2) inside tumors? Magnetic Resonance in Medicine, 48, 980-986.
87. Diergarten, T., Martirosian, P., Kottke, R., Vogel, U., Stenzl, A., Claussen, C. D. et al. (2005). Functional characterization of prostate cancer by integrated magnetic resonance imaging and oxygenation changes during carbogen breathing. Investigative Radiology, 40, 102-109.
88. Rijpkema, M., Schuuring, J., Bernsen, P. L., Bernsen, H. J., Kaanders, J. H., van der Kogel, A. J. et al. (2004). BOLD MRI response to hypercapnic hyperoxia in patients with meningiomas: Correlation with Gadolinium-DTPA uptake rate. Magnetic Resonance Imaging, 22, 761-767.
89. Howe, F. A., Robinson, S. P., McIntyre, D. J., Stubbs, M., & Griffiths, J. R. (2001). Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR in Biomedicine, 14, 497-506.
90. Rodrigues, L. M., Howe, F. A., Griffiths, J. R., & Robinson, S. P. (2004). Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. Journal of Magnetic Resonance Imaging, 19, 482-488.
91. Al-Hallaq, H. A., Zamora, M. A., Fish, B. L., Halpern, H. J., Moulder, J. E., & Karczmar, G. S. (2003). Using high spectral and spatial resolution bold MRI to choose the optimal oxygenating treatment for individual cancer patients. Advances in Experimental Medicine and Biology, 530, 433-440.
92. Swartz, H. M., & Clarkson, R. B. (1998). The measurement of oxygen in vivo using EPR techniques. Physics in Medicine & Biology, 43, 1957-1975.
93. Liu, K. J., Grinstaff, M. W., Jiang, J., Suslick, K. S., Swartz, H. M., & Wang, W. (1994). In vivo measurement of oxygen concentration using sonochemically synthesized microspheres. Biophysical Journal, 67, 896-901.
94. Ilangovan, G., Li, H., Zweier, J. L., Krishna, M. C., Mitchell, J. B., & Kuppusamy, P. (2002). In vivo measurement of regional oxygenation and imaging of redox status in RIF-1 murine tumor: Effect of carbogen-breathing. Magnetic Resonance in Medicine, 48, 723-730.
95. Matsumoto, K., Chandrika, B., Lohman, J. A., Mitchell, J. B., Krishna, M. C., & Subramanian, S. (2003). Application of continuous-wave EPR spectral-spatial image reconstruction techniques for in vivo oxymetry: Comparison of projection reconstruction and constant-time modalities. Magnetic Resonance in Medicine, 50, 865-874.
96. Elas, M., Williams, B. B., Parasca, A., Mailer, C., Pelizzari, C. A., Lewis, M. A. et al. (2003). Quantitative tumor oxymetric images from 4D electron paramagnetic resonance imaging (EPRI): Methodology and comparison with blood oxygen level-dependent (BOLD) MRI. Magnetic Resonance in Medicine, 49, 682-691.
97. Matsumoto, K., English, S., Yoo, J., Yamada, K., Devasahayam, N., Cook, J. A. et al. (2004). Pharmacokinetics of a triarylmethyl-type paramagnetic spin probe used in EPR oximetry. Magnetic Resonance in Medicine, 52, 885-892.
98. Li, H., Deng, Y., He, G., Kuppusamy, P., Lurie, D. J., & Zweier, J. L. (2002). Proton electron double resonance imaging of the in vivo distribution and clearance of a triaryl methyl radical in mice. Magnetic Resonance in Medicine, 48, 530-534.
99. Krishna, M. C., English, S., Yamada, K., Yoo, J., Murugesan, R., Devasahayam, N. et al. (2002). Overhauser enhanced magnetic resonance imaging for tumor oximetry: Coregistration of tumor anatomy and tissue oxygen concentration. Proceedings of the National Academy of Sciences of the United States of America, 99, 2216-2221.
100. Hull, E. L., Conover, D. L., & Foster, T. H. (1999). Carbogen-induced changes in rat mammary tumour oxygenation reported by near infrared spectroscopy. British Journal of Cancer, 79, 1709-1716.
101. Madsen, P. L., & Secher, N. H. (1999). Near-infrared oximetry of the brain. Progress in Neurobiology, 58, 541-560.
102. 2 mapping. Journal of Biomedical Optics, 8, 53-62.
103. Cheng, X., Mao, J. M., Bush, R., Kopans, D. B., Moore, R. H., & Chorlton, M. (2003). Breast cancer detection by mapping hemoglobin concentration and oxygen saturation. Applied Optics, 42, 6412-6421.
104. Marten, K., Bremer, C., Khazaie, K., Sameni, M., Sloane, B., Tung, C. H. et al. (2002). Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology, 122, 406-414.
105. Ziemer, L. S., Lee, W. M., Vinogradov, S. A., Sehgal, C. M., & Wilson, D. F. (2005). Oxygen distribution in murine tumors: Characterization using oxygen-dependent quenching of phosphorescence. Journal of Applied Physiology, 98, 1503-1510.
106. Wilson, D. F., Vinogradov, S. A., Dugan, B. W., Biruski, D., Waldron, L., & Evans, S. A. (2002). Measurement of tumor oxygenation using new frequency domain phosphorometers. Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology, 132, 153-159.